Izvorni znanstveni članak
INTEGRATED THERAPY WITH GLP-1 RECEPTOR AGONISTS AND NUTRITIONAL INTERVENTIONS IN THE TREATMENT OF OBESITY IN PATIENTS WITH TYPE 2 DIABETES
Mirsad Šljivić
; University Clinical Center Tuzla, Trnovac bb, 75 000 Tuzla, Bosnia and Herzegovina
*
Midhat Jašić
orcid.org/0000-0003-2507-8253
; University of Tuzla, Faculty of Pharmacy, Univerzitetska 8, 75 000 Tuzla, Bosnia and Herzegovina
Mugdim Bajrić
; University Clinical Center Tuzla, Trnovac bb, 75 000 Tuzla, Bosnia and Herzegovina
Jusuf Hodžić
; University Clinical Center Tuzla, Trnovac bb, 75 000 Tuzla, Bosnia and Herzegovina
Dženad Jusić
; Primary Healthcare Center Bugojno, Ambasadora Wagnera 15, 70 230 Bugojno, Bosnia and Herzegovina
Drago Šubarić
; Josip Juraj Strossmayer University of Osijek, Faculty of Food Technology Osijek, Franje Kuhača 18, 31000 Osijek, Croatia
Aleksandar Aleksovski
; Bacthera AG, Hochbergerstrasse 60A, 4057 Basel, Switzerland
Anja Divković
orcid.org/0000-0002-3078-688X
; University of Tuzla, Faculty of Pharmacy, Univerzitetska 8, 75 000 Tuzla, Bosnia and Herzegovina
* Dopisni autor.
Sažetak
Obesity and type 2 diabetes represent a major public health challenge, and their strong interrelationship requires integrated therapeutic approaches. GLP-1 receptor agonists have, in recent years, taken a central role in the pharmacotherapy of diabetes and obesity due to their effects on appetite regulation, body weight reduction, and glycaemic control. At the same time, wellstructured medical nutrition therapy remains the foundation of non-pharmacological weightmanagement strategies. However, the combination of GLP-1 receptor agonists with individualized dietary interventions is still insufficiently explored in real-world clinical settings. The aim of this study was to investigate the effects of combined therapy with GLP-1 RA and nutritional interventions in patients with type 2 diabetes and obesity, and to compare the findings with those reported in the SUSTAIN and LEADER clinical trial programs. Parameters monitored over a six-month period included body weight, body mass index, waist circumference, HbA1c, blood pressure, lipid profile, renal parameters, and liver enzymes. The results show that combined therapy leads to statistically and clinically significant improvements in all major metabolic outcomes. Body weight decreased by −8.60 kg (−7.82%), BMI by −3.14 kg/m², waist circumference by −4.97 cm, and HbA1c by −1.99%. Additionally, moderate reductions in blood pressure, total cholesterol, and ALT levels were observed. The findings indicate that the combination of GLP-1 RA and well-guided nutritional therapy produces stronger effects than those reported in the SUSTAIN and LEADER programs. This study confirms that an integrated approach, combining pharmacological therapy with individualized nutritional support, represents an optimal model for managing obesity in patients with type 2 diabetes.
Ključne riječi
GLP-1 RA; semaglutide; liraglutide; obesity; type 2 diabetes; medical nutrition therapy
Hrčak ID:
342877
URI
Datum izdavanja:
31.12.2025.
Posjeta: 438 *